Analyzing Tyra Biosciences (NASDAQ:TYRA) and Invizyne Technologies (NASDAQ:IZTC)

Tyra Biosciences (NASDAQ:TYRA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Tyra Biosciences and Invizyne Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95 million	($2.40)	-10.70
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations and price targets for Tyra Biosciences and Invizyne Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1	1	12	1	2.87
Invizyne Technologies	0	0	0	0	0.00

Tyra Biosciences currently has a consensus target price of $46.90, suggesting a potential upside of 82.56%. Given Tyra Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Tyra Biosciences is more favorable than Invizyne Technologies.

Insider & Institutional Ownership

84.1% of Tyra Biosciences shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Tyra Biosciences and Invizyne Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Invizyne Technologies	N/A	N/A	N/A

Summary

Tyra Biosciences beats Invizyne Technologies on 6 of the 8 factors compared between the two stocks.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.